Unresolved issues in lipid-lowering treatment

Area of Science:

• Cardiology
• Lipidology
• Preventive Medicine

Background:

• Elevated low-density lipoprotein cholesterol (LDL-C) is a primary modifiable risk factor for cardiovascular disease (CVD).
• Statins effectively reduce cardiovascular morbidity and mortality in diverse patient populations.
• Current dyslipidemia management faces unresolved questions regarding optimal LDL-C targets and the role of HDL-C.

Purpose of the Study:

• To critically evaluate optimal LDL-C levels for cardiovascular risk reduction.
• To assess the role of high-density lipoprotein cholesterol (HDL-C) in atherosclerosis and its potential as a treatment target.

Main Methods:

• Review of accumulating data from observational studies.
• Analysis of interventional studies involving statins and other lipid-lowering agents.
• Synthesis of evidence regarding LDL-C lowering and HDL-C manipulation in CVD.

Main Results:

• Considerably lowering LDL-C below current targets is safe and offers further cardiovascular risk reduction, particularly in very high-risk individuals with established CVD.
• Evidence suggests that HDL-C may not be causally linked to atherosclerosis, and increasing HDL-C levels may not consistently reduce cardiovascular risk.
• Uncertainty regarding HDL-C's role is amplified in patients achieving very low LDL-C levels with statin therapy.

Conclusions:

• Aggressive LDL-C lowering is a safe and effective strategy for reducing cardiovascular events, especially in high-risk populations.
• The clinical benefit of targeting HDL-C remains questionable and requires further investigation.
• Future research should clarify the independent role of HDL-C in cardiovascular pathogenesis and treatment efficacy.